Welcome to VivoMedica Welcome to VivoMedica

Welcome to VivoMedica

VivoMedica PLC is an AIM listed British company that delivers high value technology solutions to the global Pharmaceutical Industry. These specialist Pharma-Ware solutions are designed to improve the cost, efficiency and effectiveness of the complex processes involved in the discovery and development of drugs, and in their effective use in treatment pathways. Our company identifies, licenses and develops technologies that support these crucial process developments, and integrates them into products and service offerings that address the challenging needs of the global healthcare market.

VivoMedica’s initial portfolio of products is developed from a suite of patented healthcare technologies licensed from QinetiQ, and provides innovative solutions in the fields of cardiotoxicity testing in drug development (DrugPrint®), and in digital image analysis in cancer diagnosis (PathScore).

 

Latest News

CDI and VivoMedica present first human data
VivoMedica jointly with Cellular Dynamics Int'l presented the application of CDI's human Stem Cell-derived cardiomyocytes with DrugPrint® at SPS in Madison WI USA.
»  Read More
DrugPrint® could cut the cost of preclinical research
DrugPrint®, a novel technology for lead compound cardiotoxicity profiling could provide a way to reduce the number of drug casualties in the early stages of drug discovery.
 »  Read More

Financial News

VivoMedica shareholders approve delisting from AIM.
At the General Meeting today shareholders voted in favour of the resolution to delist the company's ordinary shares from trading on the AIM stock market.
 »  Read More